SCHEMBL6677326

SCHEMBL6677326

COc1ccc(NS(=O)(=O)c2c(F)c(F)c(Br)c(F)c2F)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.58
SMN1; SMN2 Q16637 5/20 0.58
HTT P42858 4/20 0.58
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
SHMT2 P34897 2/20 0.51
ALDH1A1 P00352 2/20 0.51
PKM P14618 1/20 0.51
TSHR P16473 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
ALOX15 P16050 2/20 0.50
MAPK1 P28482 2/20 0.50
HTR6 P50406 1/20 0.50
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6681299 0.97 SMN1; SMN2 (0.56) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6087608 0.91 SMN1; SMN2 (0.65) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6675578 0.90 HTR6 (0.52) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6681264 0.88 HTR6 (0.47) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6673920 0.88 HTR6 (0.50) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6673889 0.86 LMNA (0.58) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6676083 0.86 HTR6 (0.46) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6087510 0.84 LMNA (0.55) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6676297 0.84 HTR6 (0.53) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6678348 0.83 SMN1; SMN2 (0.56) LMNASMN1; SMN2HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed
EP-1005453-B1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS TULARIK INC (US) 2004-10-27 EP disclosed
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US disclosed
US-6284923-B1 BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS TULARIK INC 2001-09-04 US disclosed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP disclosed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 LMNA 2006/4885SMN1; SMN2 4446/4885HTT 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.